Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sutro Biopharma Inc (DE:S09)
FRANKFURT:S09
Sutro Biopharma (S09) Stock Price & Analysis
0 Followers
S09 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€1.91 - €5.45
Previous Close€3.52
Volume0.00
Average Volume (3M)N/A
Market Cap
€273.09M
Enterprise Value-€49.03M
Total Cash (Recent Filing)$375.62M
Total Debt (Recent Filing)$33.63M
Price to Earnings (P/E)N/A
Beta0.95
Next Earnings
May 14, 2024EPS Estimate
-€0.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding62,441,963
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)1.59
Price to Sales (P/S)1.45
Price to Cash Flow (P/CF)4.20
P/FCF Ratio4.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.32
Enterprise Value/Gross Profit-0.32
Enterprise Value/Ebitda1.16
Forecast
1Y Price Target
€11.25Price Target Upside219.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Sutro Biopharma News
PremiumCompany Announcements
Sutro Biopharma Secures Major Deal with Ipsen for STRO-003
Bulls Say, Bears Say
Bulls Say
Drug Development ProgressThe initiation of three new trials for Luvelta in varying cancer types highlights Sutro Biopharma's potential for growth and signals progress in their clinical development pipeline.
Market Potential And Regulatory ConfidenceLuvelta's potential to serve a broader patient population in platinum-resistant ovarian cancer, coupled with the FDA's willingness to allow dosing over 50 patients, underscores confidence in the drug's efficacy and safety profile.
Partnership And Financial ImpactSutro Biopharma's partnership with Ipsen for the global rights of STRO-003 could enhance the company's credibility and provide financial benefits through upfront payments, milestones, and royalties.
Bears Say
Clinical TrialsPart 1 REFRaME-01 enrollment to be complete with unclear outcomes for the initial 50 patients.
Drug DevelopmentSutro does not intend to pursue development of STRO-001 further, following the termination of BioNova’s collaboration agreement.
Safety ConcernsSignificant safety concerns involving ocular toxicity with competitor Elahere.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.11% Other Institutional Investors
99.89% Public Companies and
Individual Investors
S09 FAQ
What was Sutro Biopharma Inc’s price range in the past 12 months?
Sutro Biopharma Inc lowest stock price was €1.91 and its highest was €5.45 in the past 12 months.
What is Sutro Biopharma Inc’s market cap?
Currently, no data Available
When is Sutro Biopharma Inc’s upcoming earnings report date?
Sutro Biopharma Inc’s upcoming earnings report date is May 14, 2024 which is in 24 days.
How were Sutro Biopharma Inc’s earnings last quarter?
Sutro Biopharma Inc released its earnings results on Mar 25, 2024. The company reported €0.49 earnings per share for the quarter, beating the consensus estimate of -€0.255 by €0.745.
Is Sutro Biopharma Inc overvalued?
According to Wall Street analysts Sutro Biopharma Inc’s price is currently Undervalued.
Does Sutro Biopharma Inc pay dividends?
Sutro Biopharma Inc does not currently pay dividends.
What is Sutro Biopharma Inc’s EPS estimate?
Sutro Biopharma Inc’s EPS estimate is -€0.86.
How many shares outstanding does Sutro Biopharma Inc have?
Currently, no data Available
What happened to Sutro Biopharma Inc’s price movement after its last earnings report?
Sutro Biopharma Inc reported an EPS of €0.49 in its last earnings report, beating expectations of -€0.255. Following the earnings report the stock price went up 7.237%.
Which hedge fund is a major shareholder of Sutro Biopharma Inc?
Among the largest hedge funds holding Sutro Biopharma Inc’s share is Fisher Asset Management LLC. It holds Sutro Biopharma Inc’s shares valued at 843K.
---
Sutro Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€11.25 (219.48% Upside)
€11.25 (219.48% Upside)
Blogger Sentiment
Bullish
DE:S09 Sentiment 100%
Sector Average 69%
Sector Average 69%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-18.80%
12-Months-Change
Fundamentals
Return on Equity
-58.25%
Trailing 12-Months
Asset Growth
15.68%
Trailing 12-Months
Company Description
Sutro Biopharma Inc
Sutro Biopharma Inc. engages in the drug discovery, development and manufacturing of pharmaceutical products. Its products technologies include XpressCF, anti-body drug conjugates, bispecifics & engineered antibodies and cGMP facility. The company was founded by James R. Swartz and Sutanto Widjaja in June 2003 and is headquartered in South San Francisco, CA.
---
S09 Stock 12 Months Forecast
Average Price Target
€11.25
▲(219.48% Upside)
Technical Analysis
Best Analysts Covering S09
1 Year
1 Year Success Rate
5/13 ratings generated profit
1 Year Average Return
+1.72%
reiterated a buy rating 17 days ago
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of +1.72% per trade.
---